Company intelligence / Profile preview

Macomics

Edinburgh, United Kingdommacomics.com ↗

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Macomics has developed a proprietary technology platform to identify and validate novel therapeutic targets in tumour-associated macrophages. The company’s diversified portfolio of antibody programs are currently pre-clinical, with the aim to modulate TAMs and enhance anti-tumor immune responses. No clinical results have been published yet as all programs are preclinical

Therapeutic areas: Oncology
Modalities: AntibodyMonoclonal antibody
Industry: Biotech

Drug pipeline

5 assets

UNDISCLOSED-1

Preclinical

4 more assets in the full pipeline.

Request access →

Partnerships

No major pharmaceutical partnerships publicly announced as of June 2025.

Beyond the preview

Go deeper on Macomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Macomics.

Explore the full profile